Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director · CHIEF EXECUTIVE OFFICER | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 595,866 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Sale · Disposed 6,167 · Balance 597,504 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-10-05 · Sale · Disposed 1,638 · Balance 595,866 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.525 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2021 Filed Apr 30, 2021 22:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,460 | $32.30 | $47,158.00 |
DisclosureSEC source: 0001209191-21-029349 · doc4.xml · nonDerivative · entry 4 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,934 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.80 inclusive. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 22:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 14,348 | $31.22 | $447,944.56 |
DisclosureSEC source: 0001209191-21-029349 · doc4.xml · nonDerivative · entry 3 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,394 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.97 inclusive. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 22:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 6,487 | $30.43 | $197,399.41 |
DisclosureSEC source: 0001209191-21-029349 · doc4.xml · nonDerivative · entry 2 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,742 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8) and (9). Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 22:14 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 22,495 | $14.00 | $314,930.00 |
DisclosureSEC source: 0001209191-21-029349 · doc4.xml · nonDerivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 358 | $31.41 | $11,244.78 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · nonDerivative · entry 6 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,734 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $31.46 inclusive. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 6,278 | $30.66 | $192,483.48 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · nonDerivative · entry 5 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,092 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.31 to $31.27 inclusive. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 6,636 | $14.00 | $92,904.00 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · nonDerivative · entry 4 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,636 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · derivative · entry 8 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,071 Underlying: Ordinary Shares · 6,636 shares Expires 2029-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,545 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · derivative · entry 7 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,707 Underlying: Ordinary Shares · 14,545 shares Expires 2029-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 13,896 | $31.50 | $437,724.00 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · nonDerivative · entry 3 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,734 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.73 inclusive. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 4,715 | $30.63 | $144,420.45 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · nonDerivative · entry 2 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,630 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.07 to $31.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 14,545 | $14.00 | $203,630.00 |
DisclosureSEC source: 0001209191-21-028813 · doc4.xml · nonDerivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:28 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 100 | $31.00 | $3,100.00 |
DisclosureSEC source: 0001209191-21-008902 · doc4.xml · nonDerivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,800 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 21:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 351 | $33.00 | $11,583.00 |
DisclosureSEC source: 0001209191-21-004672 · doc4.xml · nonDerivative · entry 6 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,900 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 21:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 100 | $32.02 | $3,202.00 |
DisclosureSEC source: 0001209191-21-004672 · doc4.xml · nonDerivative · entry 5 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,251 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 21:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 734 | $31.33 | $22,994.16 |
DisclosureSEC source: 0001209191-21-004672 · doc4.xml · nonDerivative · entry 4 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,351 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 100 | $31.09 | $3,109.00 |
DisclosureSEC source: 0001209191-21-004672 · doc4.xml · nonDerivative · entry 3 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,085 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 371 | $30.22 | $11,211.36 |
DisclosureSEC source: 0001209191-21-004672 · doc4.xml · nonDerivative · entry 2 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,185 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:34 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 4,529 | $29.14 | $131,970.08 |
DisclosureSEC source: 0001209191-21-004672 · doc4.xml · nonDerivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,556 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2021 Filed Jan 15, 2021 21:40 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 5,000 | $27.01 | $135,050.00 |
DisclosureSEC source: 0001209191-21-003822 · doc4.xml · nonDerivative · entry 2 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,085 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:40 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0001209191-21-003822 · doc4.xml · nonDerivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,085 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:42 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001209191-21-001400 · doc4.xml · derivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 4, 2022 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:08 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 210,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-001990 · doc4.xml · derivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Ordinary Shares · 210,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month therafter. Read SEC document |
| June 28, 2019 Filed Apr 27, 2020 20:48 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 506,252 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025816 · doc4a.xml · derivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,252 Underlying: Ordinary Shares · 506,252 shares Expires 2029-06-28 F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. Read SEC document |
| May 28, 2019 Filed May 31, 2019 01:25 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 506,252 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-032912 · a4.xml · derivative · entry 1 Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,252 Underlying: Ordinary Shares · 506,252 shares Expires 2029-05-28 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.